Traditional MedicareCoverageMedium impact
MolDX: Blood Product Molecular Antigen Typing
Medicare/CMS - LCD·Hematology, Pathology·Local Coverage Determination
Effective date
Apr 16, 2026
We identified it
Jun 17, 2026
Summary
CGS Administrators has issued a new Local Coverage Determination (LCD L38249) for Blood Product Molecular Antigen Typing under the MolDX program, effective April 16, 2026. This policy will establish coverage criteria and billing requirements for molecular testing used to determine blood product compatibility.
Action Required
By April 16, 2026: Review the full LCD L38249 policy text at cms.gov to identify specific CPT/HCPCS codes, coverage criteria, and documentation requirements for blood product molecular antigen typing. Laboratory and hematology teams should update billing procedures and ensure compliance with new MolDX requirements. Verify which molecular testing procedures are affected and update prior authorization workflows if required.